Mercilon (Desogestrel, Ethinylestradiol)

The desogestrel component suppresses the release of luteinising hormone and follicle‑stimulating hormone, stopping ovulation. Ethinylestradiol stabilises the uterine lining and, together with desogestrel, thickens cervical mucus, making it difficult for sperm to reach an egg and reducing the chance of implantation.

The dosing regimen for Mercilon is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule and duration should follow the prescriber’s instructions.

Mercilon is intended for use only when pregnancy is not desired. It should not be started during an existing pregnancy. Women who are breastfeeding should discuss alternative contraceptive options with their clinician, as hormonal contraceptives may affect milk production.

To order Mercilon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mercilon contains a low‑dose estrogen (0.02 mg ethinylestradiol) combined with desogestrel, which is associated with a lower risk of certain hormonal side effects compared with higher‑dose formulations. Its efficacy in preventing pregnancy is comparable to other approved combined oral contraceptives, while offering a favorable bleeding profile for many users.

Mercilon tablets should be stored at ambient temperature, below 25 °C, in their original blister pack. Keep them away from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Mercilon is taken orally as a single tablet each day, preferably at the same time each day. The tablet should be swallowed whole with water and not chewed or broken. Consistent daily intake ensures optimal contraceptive effectiveness.

Serious risks, though rare, include blood clots such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Women with a history of clotting disorders, smoking, or certain cardiovascular conditions should discuss these risks with their healthcare provider before starting Mercilon.

Mercilon is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, severe liver disease, uncontrolled hypertension, or are smokers over the age of 35. Anyone with these conditions should seek alternative contraceptive methods.